A new study introduces InflaMix, a groundbreaking tool that could transform how clinicians assess treatment risk in patients with non-Hodgkin lymphoma (NHL) undergoing chimeric antigen receptor T cell (CAR-T) therapy. Developed by researchers using data from 149 NHL patients, InflaMix integrates 14 pre-treatment laboratory and cytokine markers to quantify inflammation and organ function, helping to predict treatment success.
The study showed that patients identified by InflaMix as high-risk were nearly three times more likely to experience death or relapse following CAR-T therapy (hazard ratio 2.98; 95% confidence interval, 1.60–4.91; P < 0.001). The model’s effectiveness was validated across three independent cohorts comprising 688 patients from diverse treatment centres. In all cases, InflaMix reliably pinpointed individuals at greater risk of poor outcomes and outperformed several existing prognostic tools.
Notably, InflaMix demonstrated strong predictive accuracy even when data was incomplete. When restricted to just six commonly available laboratory measures, it continued to deliver robust results, enhancing its real-world clinical applicability.
Reference
Raj SS et al. An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma. Nat Med. 2025 Apr;31(4):1183-1194.
